discontinued 2001 · 2 listed
newest 2001spec sheet8 rows
Adrogolide is a water-soluble prodrug that rapidly converts in plasma to A-86929, a highly selective full agonist at dopamine D1 receptors. It was investigated by Abbott Laboratories and DrugAbuse Sciences for Parkinson's disease and cocaine dependence but development was discontinued in 2001.
- Studied for Parkinson's disease motor symptoms with efficacy comparable to L-DOPA in short trials
- Studied for reducing cocaine craving and self-administration in dependent individuals
- Investigated for cognitive impairment applications
- Injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, dizziness
Overview
One of the few full D1 dopamine agonists ever tested in people; it worked about as well as L-DOPA for Parkinson's symptoms in short studies but never made it to market.
Mechanism
Adrogolide is a diacetate ester that is rapidly (in under a minute) converted in plasma to A-86929, which acts as a full at and D5 receptors with over 400-fold selectivity for D1-like over -like receptors. This selective D1 activation improved motor disability and locomotor activity in Parkinsonian animal models and produced antiparkinsonian efficacy comparable to L-DOPA in patients when given intravenously.
receptor fingerprint
receptorAgonist
D5 receptorAgonist
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Reported adverse effects in clinical testing included injection site reactions, asthenia (weakness), headache, nausea, vomiting, postural hypotension, vasodilation, and dizziness. Oral bioavailability was poor (under 4%), which along with a short 3 to 4 hour half-life limited its practicality; development was ultimately discontinued in 2001.
Subjective profileweighing the evidence above
Of historical interest only. Matching L-DOPA in short trials was a real result, but under 4 percent oral bioavailability and a three to four hour half-life made it impractical, and development stopped in 2001. Nothing to seek out.
Resources
This entry is here for reference.
Research
- 1.Adrogolide HCl (ABT-431; DAS-431), a prodrug of the dopamine D1 receptor agonist, A-86929: preclinical pharmacology and clinical data
- 2.Effects of the novel D1 dopamine receptor agonist ABT-431 on cocaine self-administration and reinstatement
2 listed here; entry last updated July 2026
Reviews
My notesprivate to this device
FAQ
What is Adrogolide used for?
It was studied as a treatment for Parkinson's disease motor symptoms and for reducing craving in cocaine dependence, but it was never approved and development stopped in 2001.
How does Adrogolide work?
It is a prodrug that converts in the blood to A-86929, a compound that strongly and selectively activates dopamine D1 receptors, which are involved in motor control.
Is Adrogolide well-researched?
It went through preclinical and Phase II clinical studies with published results, including intravenous dosing in Parkinson's patients, but was discontinued before reaching later-stage trials.
Limitations of the evidence
- Poor oral bioavailability (under 4 percent) and short half-life limited practical use
Adverse effects
- Injection site reactions, asthenia, headache, nausea, vomiting, postural hypotension, vasodilation, dizziness